Mechanical strain increases SPARC levels in podocytes: Implications for glomerulosclerosis

American Journal of Physiology - Renal Physiology

Volumn 289, Issue 3 58-3, 2005, Pages

  Durvasula, Raghu V ^a   Shankland, Stuart J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Glomerular capillary hypertension; Osteonectin; Secreted protein acidic and rich in cysteine; Stretch

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEONECTIN;

ANIMAL CELL; ARTICLE; CAPILLARY PRESSURE; CELL COUNT; CELL LOSS; CELL LYSATE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; IMMUNOHISTOCHEMISTRY; KIDNEY INJURY; MECHANICAL STRESS; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL;

EID: 23944486879     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00393.2004     Document Type: Article

References (42)

1. Alpers CE, Hudkins KL, Segerer S, Sage EH, Pichler R, Couser WG, Johnson RJ, and Bassuk JA. Localization of SPARC in developing, mature, and chronically injured human allograft kidneys. Kidney Int 62: 2073-2086, 2002.
2. Bassuk JA, Birkebak T, Rothmier JD, Clark JM, Bradshaw A, Muchowski PJ, Howe CC, Clark JI, and Sage EH. Disruption of the Sparc locus in mice alters the differentiation of lenticular epithelial cells and leads to cataract formation. Exp Eye Res 68: 321-331, 1999.
3. 1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney Int 57: 117-128, 2000.
4. Bradshaw AD, Francki A, Motamed K, Howe C, and Sage EH. Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Mol Biol Cell 10: 1569-1579, 1999.
5. Bradshaw AD and Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107: 1049-1054, 2001.
6. Brekken RA and Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19: 816-827, 2001.
7. Brenner BM. Nephron adaptation to renal injury or ablation. Am J Physiol Renal Fluid Electrolyte Physiol 249: F324-F337, 1985.
8. Brenner BM and Zagrobelny J. Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors. Kidney Int Suppl 83: S77-S85, 2003.
9. Davies SP, Reddy H, Caivano M, and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
10. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, and Shankland SJ. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65: 30-39, 2004.
11. Dworkin LD and Feiner HD. Glomerular injury in uninephrectomized spontaneously hypertensive rats. A consequence of glomerular capillary hypertension. J Clin Invest 77: 797-809, 1986.
12. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, and Endlich K. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12: 413-422, 2001.
13. Floege J, Alpers CE, Sage EH, Pritzl P, Gordon K, Johnson RJ, and Couser WG. Markers of complement-dependent and complement-independent glomerular visceral epithelial cell injury in vivo. Expression of antiadhesive proteins and cytoskeletal changes. Lab Invest 67: 486-497, 1992.
14. 1-dependent signaling in primary glomerular mesangial cells. J Cell Biochem 91: 915-925, 2004.
15. Fujita T, Shiba H, Van Dyke TE, and Kurihara H. Differential effects of growth factors and cytokines on the synthesis of SPARC, DNA, fibronectin and alkaline phosphatase activity in human periodontal ligament cells. Cell Biol Int 28: 281-286, 2004.
16. Gooden MD, Vernon RB, Bassuk JA, and Sage EH. Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix. J Cell Biochem 74: 152-167, 1999.
17. Griffin SV, Hiromura K, Pippin J, Petermann AT, Blonski MJ, Krofft R, Takahashi S, Kulkarni AB, and Shankland SJ. Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol 165: 1175-1185, 2004.
18. Harris RC, Haralson MA, and Badr KF. Continuous stretch-relaxation in culture alters rat mesangial cell morphology, growth characteristics, and metabolic activity. Lab Invest 66: 548-554, 1992.
19. Hiromura K, Haseley LA, Zhang P, Monkawa T, Durvasula R, Petermann AT, Alpers CE, Mundel P, and Shankland SJ. Podocyte expression of the CDK inhibitor p57 during development and disease. Kidney Int 60: 2235-2246, 2001.
20. Kanauchi M, Nishioka M, and Dohi K. Secreted protein acidic and rich in cysteine (SPARC) in patients with diabetic nephropathy and tubulointerstitial injury. Diabetologia 43: 1076-1077, 2000.
21. Kretzler M, Koeppen-Hagemann I, and Kriz W. Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised- desoxycorticosterone hypertensive rat. Virchows Arch 425: 181-193, 1994.
22. Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hageman I, Tenschert S, and Lemley KV. The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl 45: S64-S72, 1994.
23. Lemley KV, Lafayette RA, Safai M, Derby G, Blouch K, Squarer A, and Myers BD. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 61: 1475-1485, 2002.
24. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
25. Meyer TW, Anderson S, and Brenner BM. Dietary protein intake and progressive glomerular sclerosis: the role of capillary hypertension and hyperperfusion in the progression of renal disease. Ann Intern Med 98: 832-838, 1983.
26. 4 receptor expression in podocytes: implications for the actin cytoskeleton. Am J Physiol Renal Physiol 286: F693-F701, 2004.
27. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, and Zeller R. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258, 1997.
28. Neuringer JR and Brenner BM. Glomerular hypertension: cause and consequence of renal injury. J Hypertens Suppl 10: S91-S97, 1992.
29. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, and Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 99: 342-348, 1997.
30. Pavenstadt H, Kriz W, and Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003.
31. Petermann A, Hiromura K, Pippin J, Blonski M, Couser WG, Kopp J, Mundel P, and Shankland SJ. Differential expression of D-type cyclins in podocytes in vitro and in vivo. Am J Pathol 164: 1417-1424, 2004.
32. Petermann AT, Hiromura K, Blonski M, Pippin J, Monkawa T, Durvasula R, Couser WG, and Shankland SJ. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 61: 40-50, 2002.
33. Petermann AT, Krofft R, Blonski M, Hiromura K, Vaughn M, Pichler R, Griffin S, Wada T, Pippin J, Durvasula R, and Shankland SJ. Podocytes that detach in experimental membranous nephropathy are viable. Kidney Int 64: 1222-1231, 2003.
34. Pichler RH, Bassuk JA, Hugo C, Reed MJ, Eng E, Gordon KL, Pippin J, Alpers CE, Couser WG, Sage EH, and Johnson RJ. SPARC is expressed by mesangial cells in experimental mesangial proliferative nephritis and inhibits platelet-derived-growth-factor-mediated mesangial cell proliferation in vitro. Am J Pathol 148: 1153-1167, 1996.
35. Sage H, Vernon RB, Decker J, Funk S, and Iruela-Arispe ML. Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. J Histochem Cytochem 37: 819-829, 1989.
36. Schiemann BJ, Neil JR, and Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Mol Biol Cell 14: 3977-3988, 2003.
37. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, and Bottinger EP. Apoptosis in podocytes induced by TGF-β and Smad7. J Clin Invest 108: 807-816, 2001.
38. Srichai MB, Konieczkowski M, Padiyar A, Konieczkowski DJ, Mukherjee A, Hayden PS, Kamat S, El-Meanawy MA, Khan S, Mundel P, Lee SB, Bruggeman LA, Schelling JR, and Sedor JR. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem 279: 14398-14408, 2004.
39. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, and Alpers CE. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 14: 968-980, 2003.
40. Tolbert EM, Weisstuch J, Feiner HD, and Dworkin LD. Onset of glomerular hypertension with aging precedes injury in the spontaneously hypertensive rat. Am J Physiol Renal Physiol 278: F839-F846, 2000.
41. Vogelmann SU, Nelson WJ, Myers BD, and Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 285: F40-F48, 2003.
42. Ziyadeh FN and Sharma K. Role of transforming growth factor-β in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int Suppl 51: S34-S36, 1995.